Skip to main content

Table 3 Association of coronary heart diseases with serum Apo B/Apo A1 ratios in T2DM patients

From: Circulating growth differentiation factor 15 levels and apolipoprotein B to apolipoprotein A1 ratio in coronary artery disease patients with type 2 diabetes mellitus

ApoB/ApoA1 quartiles n Ratio range OR (95%CI)
Crude Model 1 Model 2
Quartile 1(low) 122 ≤0.5772 Reference Reference Reference
Quartile 2 130 0.5772–0.7358 1.171(1.026,2.852) 1.784(1.007,3.161) 1.310(0.580,2.961)
Quartile 3 124 0.7358–0.8716 2.850(1.707,4.759) 3.237(1.821,5.754) 2.342(1.291,7.402)
Quartile 4(high) 125 ≥0.8716 2.867(1.714,4.798) 3.327(1.864,5.940) 2.388(1.891,10.245)
β    −0.366 −0.286 −0.351
SE    0.083 0.091 0.135
p value    < 0.001 < 0.002 0.001
  1. Logistic regression was used to examine the associations between serum levels of GDF-15 and coronary artery diseases in T2DM patients. Serum GDF-15 was divided into quartiles (quartile 4: ≥75th, quartile 3: 50–75th, quartile 2: 25–50th, quartile 1: < 25th percentile)
  2. Crude: no adjustment
  3. Model 1: adjusted for age, gender, diabetic durations, BMI, alcohol drinking, smoking, hypertension, insulin, metformin and anti-hypertension treatments
  4. Model 2: adjusted for the same variables as Model 1 as well as GDF-15, WBC, NEU, LYM, NLR, hs-CRP, HbA1c, FPG, 2hPG, GA, GA/ALB, ALT, AST, GGT, Urea, Cr, UA, eGFR, FFA, TC, TG, HDL-C, and LDL-C